Hepatitis C
EASL 2011: Once-Daily BI 201335 Ups Response to Interferon for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 15 April 2011 05:47
Boerhinger Ingelheim's experimental HCV protease inhibitor BI 201335 added to pegylated interferon and ribavirin improved sustained response rates for both treatment-naive and treatment-experienced genotype 1 patients, researchers reported at EASL 2011. 
EASL 2011: BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 April 2011 14:11
About 90% of treatment-naive genotype 1 hepatitis C patients achieved sustained response at 12 weeks post-treatment using the experimental HCV protease inhibitor BMS-790052 plus pegylated interferon/ribavirin, researchers reported at EASL 2011. 
EASL 2011: Telaprevir Improves HCV Cure Rates Regardless of IL28B Status
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 05 April 2011 06:57
The Vertex experimental protease inhibitor telaprevir, taken with pegylated interferon plus ribavirin, increased sustained response in people with all IL28B gene patterns, researchers reported at EASL 2011.
EASL 2011: BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 12 April 2011 14:02
Most prior non-responders with HCV genotype 1 achieved sustained response with a quadruple combination containing 2 experimental agents plus pegylated interferon/ribavirin, and nearly 40% did so using only the 2 oral drugs -- BMS-790052 and BMS-650032 -- researchers reported at EASL 2011.
Boceprevir Improves Response to Interferon-Based HCV Therapy
- Details
- Category: Approved HCV Drugs
- Published on Thursday, 31 March 2011 17:54
The HCV protease inhibitor boceprevir improved sustained response rates when combined with pegylated interferon plus ribavirin in both previously untreated patients and prior non-responders, according to findings from 2 studies published in the March 31 New England Journal of Medicine.
EASL 2011: First Sustained Response Data for HCV Polymerase Inhibitor Mericitabine
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 05 April 2011 14:14
76% of treatment-naive genotype 1 or 4 hepatitis C patients achieved 12-week sustained response to mericitabine (formerly RG7128) plus pegylated interferon/ribavirin, according to a report at EASL 2011. 
CROI 2011: Interactions of HIV Meds with HCV drugs Telaprevir and Boceprevir
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 22 March 2011 00:00
New HCV antiviral drugs can interact with some antiretroviral drugs for HIV, but others are not affected and HIV/HCV coinfected patients can be treated successfully with minimal dose adjustments.
EASL 2011: Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 05 April 2011 08:05
Almost all treatment-naive hepatitis C patients treated with Pharmasset's candidate PSI-7977 plus pegylated interferon/ribavirin experienced 12-week sustained response, and more than 90% treated with a PSI-7977 + PSI-938 all-oral combo had undetectable HCV at 14 days, researchers reported at EASL. 
New Phase 2b Study of Experimental Hepatitis C Vaccine ChronVac-C
- Details
- Category: HCV Vaccines
- Published on Friday, 18 March 2011 00:54
Inovio Pharmaceuticals this week announced that its partner ChronTech has started a new Phase 2 clinical trial to evaluate an investigational therapeutic hepatitis C virus (HCV) vaccine candidate known as ChronVac-C. In early studies the vaccine increased T-cell responses against HCV, suppressed viral load, and appeared to be safe and well-tolerated.
More Articles...
- CROI 2011: HCV Protease Inhibitor Boceprevir Improves Response for Treatment-Naive and Non-responders
- Little Overlap of Sexually Transmitted HCV between U.S. and Europe
- U.S. Hepatitis C Incidence Dropped 10-fold Over 2 Decades
- Telaprevir Improves Treatment Outcomes for HIV/HCV Coinfected People
- HCV Polymerase Inhibitor INX-189 Gets FDA Fast-Track Status, TMC649128 Enters Phase 1a Trial
Web Design and Development by